Home World News Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage... World News Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC By Ogkologos - September 17, 2026 97 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a second planned interim analysis of the AEGEAN study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Improving Care for Underserved People With Cancer and Evaluating Delays in... September 20, 2021 ASCO20 Virtual Research Round Up Podcast: Head and Neck Cancer and... August 13, 2020 Activity and Safety of Atezolizumab Combined with Carboplatin and Pemetrexed in... August 30, 2023 FDA Proposes Rule Prohibiting Menthol Cigarettes June 27, 2022 Load more HOT NEWS Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously... Foodie Fridays: Apple Bok Choy Salad Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival... EMA Recommends Extension of Indications for Venetoclax